NuvoAir is a value-based specialty management platform transforming the diagnosis and management of chronic heart and lung conditions.
NuvoAir has raised $11.0M in total funding. The most recent round was Series A. The last funding was announced in January 2022.
NuvoAir's investors include Novartis, KAYA, AlbionVC, Hikma Ventures, Industrifonden.
NuvoAir is headquartered in Boston, United States.
NuvoAir is a value-based specialty management platform transforming the diagnosis and management of chronic heart and lung conditions.
NuvoAir is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NuvoAir — Funding & Investors." VCBacked, January 19, 2022, https://www.vcbacked.co/company/nuvoair. Accessed August 14, 2026.
VCBacked. (2022). NuvoAir — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/nuvoair
{{cite web |title=NuvoAir — Funding & Investors |url=https://www.vcbacked.co/company/nuvoair |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated